Daiichi Sankyo: Diabetes Mellitus, Type 2 trials

The registry lists 30 Diabetes Mellitus, Type 2 studies with Daiichi Sankyo as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 1 3Phase 2 9Phase 3 15Phase 4 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on MetforminCompletedNCT02647320Phase 2Results posted
• Colesevelam for Children With Type 2 DiabetesCompletedNCT01258075Phase 4Results posted
• Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes MellitusCompletedNCT00789750Phase 3Results posted
• Welchol as Monotherapy for Type 2 Diabetes MellitusCompletedNCT00789737Phase 3Results posted
• Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes MellitusTerminatedNCT00571519Phase 3Results posted
• Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.CompletedNCT00570739Phase 3Results posted
• Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With MetforminCompletedNCT00484419Phase 3Results posted
• Study of Rivoglitazone in Type 2 Diabetes MellitusCompletedNCT00484198Phase 3Results posted
• Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 DiabetesCompletedNCT00147745Phase 2Results posted
• ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy TrialCompletedNCT00141453Phase 3Results posted
• An Observational Study Investigating the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 DiabetesCompletedNCT05107063
• Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and AlbuminuriaCompletedNCT02807974Phase 3
• A Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus Receiving SitagliptinCompletedNCT02685345Phase 2
• An Exploratory Study of DS-8500a on Beta Cell Function Using Hyperglycemic ClampCompletedNCT02669732Not applicable
• A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)CompletedNCT02628392Not applicable
• Phase 2 Study of DS-8500a in Patients With Type 2 DiabetesCompletedNCT02222350Phase 2
• Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes MellitusCompletedNCT02004678Phase 1
• Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose StudyCompletedNCT01956305Phase 1
• A Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes MellitusCompletedNCT01862939Phase 1
• Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 DiabetesCompletedNCT00575874Phase 2
• Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 DiabetesCompletedNCT00575471Phase 2
• Olmesartan Medoxomil and Diabetic NephropathyCompletedNCT00362960Phase 3
• Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes MellitusCompletedNCT00361153Phase 2
• Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917CompletedNCT00290940Phase 2
• Olmesartan Medoxomil in Diabetes MellitusCompletedNCT00185159Phase 3
• Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 DiabetesCompletedNCT00151762Phase 3
• WelChol® and Insulin in Treating Patients With Type 2 DiabetesCompletedNCT00151749Phase 3
• WelChol® and Sulfonylurea in Treating Patients With Type 2 DiabetesCompletedNCT00147758Phase 3
• WelChol® With Metformin in Treating Patients With Type 2 DiabetesCompletedNCT00147719Phase 3
• Placebo and Active Controlled Study of Rivoglitazone in Type 2 DiabetesCompletedNCT00143520Phase 2/3